Work

Supplementary Figure 1 from The Anti-CD19 Antibody–Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia

Year: 2023

Type: supplementary-materials

Abstract: PDF file - 3285K, Single agent efficacy of SAR3419. NOD/SCID mice engrafted with ALL-16 (A); ALL-17 (B); or MLL-14 (C) were treated with vehicle (dashed lines) or 10 mg/kg SAR3419 (solid lines) once a week for 3 weeks. The response to treatment was monitored by weekly measurements of the %huCD45+ cells in PB of individual mice (left panel). The EFS (time to reach 25% of leukemia cells in PB) is represented by Kaplan-Meier plots (right panel). Gray arrows indicate treatment time points.

DOI: 10.1158/1078-0432.22455752

Authors: Hernan Carol, Barbara Szymanska, Kathryn Evans, Ingrid Boehm, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361910919

Cites:

Cited by:

Related to: 10